Dr. Reddy’s Lab advances on launching Versavo in India

19 Aug 2019

Dr. Reddys Laboratories is currently trading at Rs. 2536.05, up by 43.25 points or 1.73% from its previous closing of Rs. 2492.80 on the BSE.

The scrip opened at Rs. 2525.00 and has touched a high and low of Rs. 2567.50 and Rs. 2515.10 respectively. So far 13233 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 2598.60 and Rs. 2352.00 respectively. The current market cap of the company is Rs. 42423.81 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.

Dr. Reddy's Laboratories has launched Versavo (bevacizumab), a biosimilar of Roche's Avastin in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer). The company’s Versavo is available in strengths of 100mg and 400mg single use vials.

The company now has six biosimilar products commercialized in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Related Dr. Reddys Laboratories Ltd. Links:

Dr. Reddys Lab Share Price

5083.50 -43.65 (-0.85%) Sep 29, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 505.60
Dr. Reddys Lab 5083.50
Lupin 998.00
Piramal Enterprises 1253.15
Cadila Healthcare 387.55
View more..
Sensex vs Dr. Reddys Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback